Profound Medical logo

Profound Medical(TSX) PRN

Market CapCA$301.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-45%
5 Year-55%
1 Year+8%
1 Month-1%
CA$8.31
+0.73%
+0.06Today
Profound Medical last closing stock price
MetricPriceDate
Last closeCAD 8.252026-10-19
Profound Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-16.07%CAD 9.832026-10-09
1 month-0.72%CAD 8.312026-09-18
3 month-15.99%CAD 9.822026-07-21
Year to date-23.4%CAD 10.772025-12-31
1 year+8.13%CAD 7.632025-10-17
3 year-33.25%CAD 12.362023-10-20
5 year-54.5%CAD 18.132021-10-20
Since inception-45%CAD 15.002015-06-09

Profound Medical Financials at a Glance

Market Cap

CA$301.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$18.97M

Net Income (TTM)

-$32.42M

EPS (TTM)

-CA$1.37

P/E Ratio

-6.04

Dividend

CA$0.00

Beta (Volatility)

1.04 (Average)

Price

CA$8.31

Volume

2,128

Open

CA$8.41

Previous Close

CA$8.25

Daily Range

CA$8.31 - CA$8.48

52-Week Range

CA$6.52 - CA$12.40

Estimated Earnings Date

Nov 5, 2026

PRN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Profound Medical

Profound Medical Corp. is a commercial-stage medical technology firm specializing in innovative magnetic resonance (MR) guided ablation therapies. The company focuses on addressing prostate conditions, uterine fibroids, and providing palliative pain management solutions.

Products and Services
  • TULSA-PRO system for prostate treatment
  • Sonalleve platform for uterine fibroids and pain management
  • Integration with MRI scanners for enhanced treatment precision
Growth Outlook
  • Expansion into new markets, including the U.S. and Germany
  • Increasing demand for non-invasive treatment options
  • Potential for strategic partnerships to enhance market reach
Financial Highlights
  • Recent quarterly revenue of 2.42 million USD, showing growth potential
  • Cash reserves of approximately 38.21 million USD as of June 2026
  • Current ratio of 6.46 indicates strong liquidity position
Profound Medical Corp. operates in a growing sector with a focus on innovative medical solutions. The TULSA-PRO system and Sonalleve platform represent significant advancements in non-invasive treatment options, catering to a rising demand for effective healthcare solutions. The company's strategic expansion into key markets and potential partnerships may further enhance its growth trajectory. Financially, the recent quarterly revenue indicates a positive trend, while the substantial cash reserves provide a solid foundation for future investments and operational stability. The strong liquidity position, as reflected in the current ratio, suggests that the company is well-equipped to navigate challenges and capitalize on opportunities in the evolving healthcare landscape.
AI Generated • Oct 20, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

162

CEO

Arun S. Menawat, PhD, EMBA

Website

www.profoundmedical.com

Headquarters

Mississauga, ON L4W 5K5, CA

PRN Financials

Key Financial Metrics (TTM)

Gross Margin

71.73%

Operating Margin

-184.35%

Net Income Margin

-170.92%

Return on Equity

-62.45%

Return on Capital

-59.11%

Return on Assets

-52.05%

Earnings Yield

-16.56%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$301.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

36.53M

Volume

2.13K

Avg. Volume

14.66K

Financials (TTM)

Gross Profit

$13.61M

Operating Income

-$34.97M

EBITDA

-$33.43M

Operating Cash Flow

-$35.61M

Capital Expenditure

-$179.09K

Free Cash Flow

-$35.79M

Cash & ST Invst.

$38.21M

Total Debt

$7.37M

Profound Medical Performance Analysis

Profound Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 8,697,6830.9%
20232023-12-31USD 9,716,39611.7%
20242024-12-31USD 14,631,19050.6%
20252025-12-31USD 22,493,55153.7%
Profound Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30136.6%
Q42025-12-3116.0%
Q12026-03-31-13.5%
Q22026-06-30-53.9%
Profound Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.79-4.7%
20232023-12-31USD -1.800.7%
20242024-12-31USD -1.54-14.7%
20252025-12-31USD -1.9727.9%
Profound Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3050.0%
Q42025-12-31-3.8%
Q12026-03-3129.6%
Q22026-06-30-31.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$2.42M

+9.4%

Gross Profit

$1.90M

+17.2%

Gross Margin

78.41%

N/A

Market Cap

CA$301.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$1.86M

N/A

Employees

162

N/A

Net Income

-$9.29M

+40.8%

EBITDA

-$10.65M

+22.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$38.21M

+8.6%

Total Debt

$7.37M

+53.1%

Accounts Receivable

$9.60M

+96.0%

Inventory

$10.44M

+25.0%

Long Term Debt

$2.75M

-39.4%

Short Term Debt

$4.62M

+728.6%

Return on Assets

-52.05%

N/A

Return on Invested Capital

-65.74%

N/A

Free Cash Flow

-$11.03M

+19.7%

Operating Cash Flow

-$11.03M

+19.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
XLY.TOAuxly Cannabis Group Inc.
CA$3.42+0.88%
DR.TOMedical Facilities Corporation
CA$14.50+1.26%
CRRX.TOCareRx Corporation
CA$3.31+0.15%
NGEN.VNervGen Pharma Corp.
CA$5.15+3.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$98.88+0.23%
CRWVCoreWeave
$62.60+2.42%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$46.40-0.50%
BITOProShares Trust - ProShares Bitcoin ETF
$11.05+1.18%

Questions About PRN

What is the current price of Profound Medical?

Profound Medical is trading at CA$8.31 per share.

What is the 52-week range for Profound Medical?

Over the past 52 weeks, Profound Medical has traded between CA$6.52 and CA$12.40.

How much debt does Profound Medical have?

As of the most recent reporting period, Profound Medical reported total debt of $10.47M.

How much cash does Profound Medical have on hand?

Profound Medical reported $54.30M in cash and cash equivalents in its most recent financial results.

What is Profound Medical’s dividend yield?

Profound Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services